1st Quarter - Report

SUMMIT HEALTH CARE CONSULTING for AMERICAN SOCIETY FOR GASTROINTESTINAL ENDOSCOPY

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Oppose Centers for Medicare and Medicaid Services' (CMS) proposal to implement an efficiency adjustment to Medicare Physician Fee Schedule payments. Support the Efficiency Adjustment Delay Act (H.R. 7520), which would stop the application of an efficiency adjustment until at least January 1, 2030. Oppose the CMS practice expense site differential proposal (no specific legislation) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation) Support the Improving Seniors Timely Access to Care Act (S. 1816, H.R. 3514) to codify CMS prior authorization regulations for MA plans and require greater transparency of prior authorization processes

LobbyistCovered position, as disclosed
CAMILLE BONTA Legislative Correspondent, U.S. Senator John Glenn

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3514 (119th), S. 1816 (119th), H.R. 7520 (119th)

Health Issues HCR

Oppose the Patients Deserve Price Tags Act (S. 2355), specifically Section 5.

LobbyistCovered position, as disclosed
CAMILLE BONTA —

Contacted: SENATE

Bills named: S. 2355 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.